43 filings
Page 2 of 3
8-K
eza1jxp0
21 Mar 22
Regulation FD Disclosure
5:12pm
8-K
drbfdpq
21 Mar 22
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021
4:07pm
8-K
fwm1j2h70cq5k1jkc4tb
4 Mar 22
Departure of Directors or Certain Officers
4:02pm
8-K
9t501e
10 Jan 22
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
8:07am
8-K
v482qp 7dqfqqze
10 Nov 21
ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors
4:21pm
8-K
qq8erpf14ia3vct
8 Nov 21
ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
4:16pm
8-K
0ekm8ulhi74xn0l0ay1
7 Oct 21
ORIC Pharmaceuticals Presents Initial Clinical Data from
4:06pm
8-K
630qpl72zw0vqpc 67q
18 Aug 21
Other Events
6:07am
8-K
6bpjl0
16 Aug 21
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
4:41pm
8-K
ztr2xwvgn5dp1zbgd
10 Aug 21
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
4:16pm
8-K
lqrqp
12 Jul 21
Other Events
5:05pm
8-K
klcl4kq
8 Jul 21
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
6:05am
8-K
xnblf
21 Jun 21
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
4:06pm
8-K
npp40ty4cjlnr
6 May 21
Entry into a Material Definitive Agreement
5:10pm
8-K
d9h8tdx
6 May 21
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
4:10pm
8-K
svmj jlw5mmkpsw7z
23 Mar 21
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020
4:10pm
8-K
l8f6g4xc8l
11 Jan 21
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones
6:36am
8-K
j7lrc2y
5 Nov 20
ORIC Pharmaceuticals Reports Third Quarter 2020
4:18pm
8-K
i8agnhge 62cl69d8jf
19 Oct 20
Other Events
4:09pm
8-K
bzk2hshn sucesov
5 Aug 20
ORIC Pharmaceuticals Reports Second Quarter 2020
4:15pm